How to Source Non-IMP Supplies for Clinical Trials
Tim Holmes, Manager, Clinical Oversight of Supplies, Biogen, offers considerations on how to obtain non-IMP...
Read More...
Focus:
-
![]()
Sandoz Abandons US Development of Rixathon
Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the implications of Sandoz’s abandoned attempt to...
Read More...
-
![]()
GDPR: The Implications for Clinical Development
Eight months in, Nigel Hughes, Scientific Director JCI-PDR, Janssen, examines the ramifications of GDPR on...
Read More...
-
![]()
Industry Viewpoints: Patient Recruitment and Expanded Access
In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges...
Read More...
-
![]()
Medical Device Development – Challenges of an SME
John Shillingford, Clinical Operations Director, Orsus Medical, describes the inherent challenges facing small- to mid-sized...
Read More...
-
![]()
MDMA Treatments Found to Eliminate PTSD Symptoms in Phase II Trial
Gavin Davidson, CVMD Analyst, GlobalData, examines how MDMA is used to treat patients with PTSD
Read More...
-
![]()
How Whole Systems Thinking Could Transform the Clinical Supply Chain
Hedley Rees, Chief Disruptor, PharmaFlow, discusses the need for a rethink on supply chain processes
Read More...
-
![]()
Managing Blinding Requirements in IRT: An Overview
Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded...
Read More...
-
![]()
Integrating New Assets: A Supply Chain Perspective
Barrett Glasser, Associate Director, Clinical Drug Supply, Biogen, provides an overview on how to on...
Read More...
-
![]()
Observations from GCP Sponsor Inspections
Kevin Anderson, Director, Global Clinical Operations, Alexion Pharmaceuticals, offers a perspective on what he has...
Read More...
